Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL711975

CCCCCC[n+]1ccn(C)c1C.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
KCNH2 Q12809 7/20 0.45
ACHE P22303 3/20 0.42
EEF2K O00418 2/20 0.36
EEF2 P13639 2/20 0.36
MEN1 O00255 1/20 0.36
PLK4 O00444 1/20 0.36
JAK2 O60674 1/20 0.36
EGFR P00533 1/20 0.36
TYK2 P29597 1/20 0.36
FLT3 P36888 1/20 0.36
BLM P54132 1/20 0.36
KMT2A Q03164 1/20 0.36
ITK Q08881 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
HTT P42858 1/20 0.34
EPHX1 P07099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL1329120 1.00 CA1 (0.47) CA1CA2KCNH2ACHEEEF2K
Trifluoromethanesulfonic Acid SCHEMBL1330197 1.00 CA1 (0.47) CA1CA2KCNH2ACHEEEF2K
Trifluoromethanesulfonic Acid SCHEMBL1329985 1.00 CA1 (0.47) CA1CA2KCNH2ACHEEEF2K
Trifluoromethanesulfonic Acid SCHEMBL707413 0.94 KCNH2 (0.41) CA1CA2KCNH2ACHEEEF2K
Trifluoromethanesulfonic Acid SCHEMBL1681506 0.89 KCNH2 (0.37) CA1CA2KCNH2ACHE
SCHEMBL23004258 0.85 CA1 (0.48) CA1CA2ACHEEEF2KEEF2
Trifluoromethanesulfonic Acid SCHEMBL1330266 0.84 KCNH2 (0.35) KCNH2ACHE
Sulfuric Acid SCHEMBL4247474 0.84 CA1 (0.44) CA1CA2EEF2KEEF2MEN1
SCHEMBL1826848 0.84 CA1 (0.61) CA1CA2KCNH2ACHEEEF2K
SCHEMBL4059675 0.84 CA1 (0.61) CA1CA2KCNH2ACHEEEF2K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY INC (US) 2021-12-23 US claimed
US-20130341561-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY, INC. (US) 2013-12-26 US claimed
US-7718579-B2 Electrochemical deblocking using a hydrazine derivative COMBIMATRIX CORPORATION (US) 2010-05-18 US claimed
EP-1869061-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY Combimatrix Corporation (US) 2007-12-26 EP claimed
EP-1805206-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE Combimatrix Corporation (US) 2007-07-11 EP claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 US claimed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 WO claimed
WO-2006131234-A1 COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-12-14 WO claimed
US-7141154-B2 utilizes a fixed resin-wafer and electrodeionization (EDI) technology to form a separative reactor that carries out the separation and reaction in a single stage process UCHICAGO ARGONNE LLC (US) 2006-11-28 US claimed
WO-2006105037-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY COMBIMATRIX CORPORATION (US) 2006-10-05 WO claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US claimed
US-20050056547-A1 Single-stage separation and esterification of cation salt carboxylates using electrodeionization THE UNIVERSITY OF CHICAGO (US) 2005-03-17 US claimed
US-20240101999-A1 HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS THERMO FISHER SCIENTIFIC GENEART GMBH (DE) 2024-03-28 US disclosed
CN-115927293-A Efficient small volume nucleic acid synthesis 生命技术公司 2023-04-07 CN disclosed
CN-107532129-B Efficient small volume nucleic acid synthesis 生命技术公司 2022-09-13 CN disclosed
US-20060139426-A1 Ink, ink set, processing solution, recording method, recording medium, ink tank, and recording device FUJI XEROX CO., LTD. 2006-06-29 US disclosed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO disclosed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US disclosed
US-20050056547-A1 Single-stage separation and esterification of cation salt carboxylates using electrodeionization THE UNIVERSITY OF CHICAGO (US) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY DNMT1, DNASE1, DNPEP CA1 195/4885CA2 1004/4885KCNH2 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.